Researchers from across the 探花直播 have been recognised for the impact of their work on society, and engagement with research in the inaugural Vice-Chancellor鈥檚 Impact Awards and Public Engagement with Research Awards.
A new drug for ovarian cancer, developed by researchers at the 探花直播 of Cambridge and AstraZeneca, has today become the first of new class of drugs, known as PARP-inhibitors, to be granted approval anywhere in the world. 探花直播drug, Lynparza, has been granted Marketing Authorisation from the European Commission.
Scientists at the 探花直播 of Cambridge have identified a key chemical that can repair the damage to cells which causes a rare but devastating disease involving accelerated ageing. As well as offering a promising new way of treating the condition, known as Hutchinson-Gilford Progeria Syndrome (HGPS), the discovery could help in the development of drugs against cancer and other genetic diseases and might also suggest ways to alleviate diseases that we associate with normal ageing.
© 2025 探花直播 of Cambridge